摘要
目的：评价替吉奥（ S-1）联合顺铂治疗进展期胃癌的近期疗效及安全性。方法56例进展期胃癌患者分为治疗组和对照组，各28例。治疗组方案为S-160 mg bid，d1～d21；顺铂静脉滴注60 mg· m-2，d1～d3，4周为1个周期。对照组方案为静脉滴注奥沙利铂125 mg · m-2， d1；静脉滴注替加氟600 mg· m-2，d1～d5；静脉滴注亚叶酸钙120 mg· m-2，d1～d5，3周为1个周期。3个周期后评价2组疗效及不良反应。结果治疗组和对照组的客观有效率分别为75.0％和42.9％，差异有统计学意义（ P＜0.05）；治疗组Ⅲ～Ⅳ级不良反应发生率明显低于对照组，差异有统计学意义（ P＜0.05）。结论 S-1联合顺铂化疗方案一线治疗进展期胃癌的近期疗效较好，不良反应可以耐受。
Objective To evaluate the short-term efficacy and toxicity of the combination of gimeracil and oteracil porassium （ S-1 ） and cispla-tin in the treatment of advanced gastric carcinoma.Methods Fifty-six patients with advanced gastric carcinoma were randomly divided into two groups with 28 cases in each group.Experimental group was treated with S-1 （60 mg bid d1 -d21） combined with cisplatin （60 mg· m-2 iv d1-d3） with 4 weeks as a cycle.While control group was treated with oxaliplatin （130 mg· m-2 iv d1）, tegafur （600 mg· m-2 iv d1-d5）, calcium folinate （ 120 mg · m-2 iv d1 -d5 ） with 3 weeks as a cycle.Short-term efficacy and adverse reactions were evaluated after three cy-cles.Results The tumor response rate of experimental group and control group was 75.0%and 42.9%（P〈0.05）.Besides, compared with the con-trol group , the occurrence of gradeⅢ-Ⅳadverse reactions in experimental group were apparently lower.Conclusion The regimen of S -1 combined with cisplatin has shown a better efficacy in the treatment of patients with ad-vanced gastric carcinoma , and the toxicity is relatively mild and tolerable .
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第7期575-576,580,共3页
The Chinese Journal of Clinical Pharmacology
基金
成都市卫生局科学研究基金资助项目(2011136)
